Suppr超能文献

蒿甲醚-本芴醇治疗印度四个疟疾流行州无并发症恶性疟的疗效。

Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India.

机构信息

ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.

Medical Officer, Balaghat, Madhya Pradesh, India.

出版信息

Malar J. 2021 May 21;20(1):229. doi: 10.1186/s12936-021-03762-7.

Abstract

BACKGROUND

Malaria is a major public health problem in India and accounts for about 88% of malaria burden in South-East Asia. India alone accounted for 2% of total malaria cases globally. Anti-malarial drug resistance is one of the major problems for malaria control and elimination programme. Artemether-lumefantrine (AL) is the first-line treatment of uncomplicated Plasmodium falciparum in north eastern states of India since 2013 after confirming the resistance against sulfadoxine-pyrimethamine. In the present study, therapeutic efficacy of artemether-lumefantrine and k13 polymorphism was assessed in uncomplicated P. falciparum malaria.

METHODS

This study was conducted at four community health centres located in Koraput district of Odisha, Bastar district of Chhattisgarh, Balaghat district of Madhya Pradesh and Gondia district of Maharashtra state. Patients with uncomplicated P. falciparum malaria were administered with fixed dose combination (6 doses) of artemether-lumefantrine for 3 days and clinical and parasitological response was recorded up to 28 days as per World Health Organization protocol. Nucleotide sequencing of msp1 and msp2 gene was performed to differentiate between recrudescence and reinfection. Amplification and sequencing of k13 propeller gene region covering codon 450-680 was also carried out to identify the polymorphism.

RESULTS

A total 376 malaria patients who fulfilled the enrolment criteria as well as consented for the study were enrolled. Total 356 patients were followed up successfully up to 28 days. Overall, the adequate clinical and parasitological response was 98.9% and 99.4% with and without PCR correction respectively. No case of early treatment failure was observed. However, four cases (1.1%) of late parasitological failure were found from the Bastar district of Chhattisgarh. Genotyping of msp1 and msp2 confirmed 2 cases each of recrudescence and reinfection, respectively. Mutation analysis of k13 propeller gene showed one non-synonymous mutation Q613H in one isolate from Bastar.

CONCLUSIONS

The study results showed that artemether-lumefantrine is highly effective in the treatment of uncomplicated P. falciparum malaria among all age groups. No functional mutation in k13 was found in the study area. The data from this study will be helpful in implementation of artemether-lumefantrine in case of treatment failure by artesunate plus sulfadoxine-pyrimethamine.

摘要

背景

疟疾是印度的一个主要公共卫生问题,占东南亚疟疾负担的约 88%。印度一国就占全球疟疾病例的 2%。抗疟药物耐药性是疟疾控制和消除规划面临的主要问题之一。自 2013 年确认对磺胺多辛-乙胺嘧啶产生耐药性以来,青蒿琥酯-咯萘啶(AL)一直是印度东北部各州治疗无并发症恶性疟原虫感染的一线药物。在本研究中,评估了青蒿琥酯-咯萘啶治疗无并发症恶性疟原虫疟疾的疗效和 K13 多态性。

方法

本研究在奥里萨邦科拉普特区、恰蒂斯加尔邦巴斯塔尔区、中央邦巴拉加特区和马哈拉施特拉邦贡迪亚区的四个社区卫生中心进行。对无并发症恶性疟原虫感染的患者给予青蒿琥酯-咯萘啶固定剂量复方(6 剂)治疗 3 天,并按照世界卫生组织方案记录临床和寄生虫学反应,直至 28 天。对 msp1 和 msp2 基因进行核苷酸测序,以区分复发和再感染。还对涵盖 450-680 密码子的 K13 螺旋桨基因区域进行扩增和测序,以鉴定多态性。

结果

共纳入符合纳入标准并同意参加研究的 376 例疟疾患者。共有 356 例患者成功随访至 28 天。总的来说,未经 PCR 校正的完全临床和寄生虫学反应分别为 98.9%和 99.4%。未观察到早期治疗失败病例。然而,恰蒂斯加尔邦巴斯塔尔区发现了 4 例(1.1%)晚期寄生虫学失败病例。msp1 和 msp2 的基因分型证实分别有 2 例复发和再感染。K13 螺旋桨基因的突变分析显示,巴斯塔尔区的一个分离株有一个非同义突变 Q613H。

结论

研究结果表明,青蒿琥酯-咯萘啶对各年龄段无并发症恶性疟原虫感染均具有高度疗效。在研究区域未发现 K13 的功能突变。本研究的数据将有助于在青蒿琥酯-甲氟喹治疗失败时实施青蒿琥酯-咯萘啶治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/510d/8139028/0646cebf0f68/12936_2021_3762_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验